Erik Cederfjäll, Ph.D.

2008-2014 B.R.A.I.N.S. Unit Lund University, Lund, Skåne län, Sweden 
 2015-2017 Molecules - Signaling - Development Max Planck Institute of Neurobiology, Jupiter, FL, United States 
Parkinson's disease | Gene therapy
"Erik Cederfjäll"
Mean distance: 17.38 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cederfjäll E, Broom L, Kirik D. (2015) Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 896-906
Cederfjäll E, Nilsson N, Sahin G, et al. (2013) Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports. 3: 2157
Cederfjäll E, Sahin G, Kirik D, et al. (2012) Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1315-26
Cederfjäll E, Sahin G, Kirik D. (2012) Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease. 48: 222-7
Björklund T, Cederfjäll EA, Kirik D. (2010) Gene therapy for dopamine replacement. Progress in Brain Research. 184: 221-35
Björklund T, Carlsson T, Cederfjäll EA, et al. (2010) Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a Journal of Neurology. 133: 496-511
See more...